Faron Pharmaceuticals Oy. (1/4/21). "Press Release: Faron to Present at H.C. Wainwright BioConnect". Turku.

	Organisation	Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON)
	Organisation 2	H.C. Wainwright & Co. LLC
	Group	H.C. Wainwright (Group)
	Product	H.C. Wainwright BioConnect Conference 2021 DIGITAL
	Product 2	Clevegen
	Index term	Faron Pharmaceuticals–HC Wainwright: investor conference, 20201 supply service Faron presents at H.C. Wainwright BioConnect Conference 2021 DIGITAL
	Person	Jalkanen, Markku (Faron Pharmaceuticals 201505 CEO)
	Person 2	Seidel, Julie (Precision Medicine Group 202003 Managing Director at Stern IR)

Faron Pharmaceuticals Ltd ("Faron") (LON: FARN), the clinical stage biopharmaceutical company, today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.

An audio webcast of the presentations will be available in the "Investors" section on Faron's website at https://www.faron.com/investors

ENDS

For more information please contact:

Stern Investor Relations, Inc.
Julie Seidel, Naina Zaman
Phone: +(1)212 362 1200
Email: faron@sternir.com

Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at www.faron.com

Record changed: 2021-01-05